Showing results (691-700 of 895) with videos related to

Sort By:
Pageof 90
Drugs in R&D|October 25, 2021
Pharmacokinetics of the Melanocortin Type 1 Receptor Agonist PL8177 After Subcutaneous AdministrationJohn Dodd, Robert Jordan, Marie Makhlina, et al.
Drugs in R&D|April 5, 2022
Pharmacokinetics and Safety of Ferric Pyrophosphate Citrate in Chinese Subjects with and without Hemodialysis-Dependent Stage 5 Chronic Kidney DiseaseLiangying Gan, Panpan Xie, Yan Tan, et al.
Drugs in R&D|November 27, 2023
Drug-Drug Interaction Studies of Esmethadone (REL-1017) Involving CYP3A4- and CYP2D6-Mediated MetabolismNicola Ferri, Sara De Martin, James Stuart, et al.
Drugs in R&D|September 12, 2023
Pharmacovigilance Study of Infigratinib: A Safety Analysis of the FDA Adverse Event Reporting SystemDehua Zhao, Xiaoqing Long, Jiping Zhou, et al.
Drugs in R&D|September 26, 2023
Effect of Tucatinib on Cardiac Repolarization in Healthy VolunteersAriel R Topletz-Erickson, JoAl G Mayor, Hsu-Tai Liu, et al.
Drugs in R&D|July 19, 2023
Efficacy and Safety of Apatinib in Patients with Recurrent GlioblastomaHao Lin, Xinli Zhou, Xiaofang Sheng, et al.
Drugs in R&D|July 21, 2023
Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference BevacizumabDi Cao, Chunping Deng, Guangying Wang, et al.
Drugs in R&D|July 9, 2023
Hepatotoxicity of AKR1C3 Inhibitor BAY1128688: Findings from an Early Terminated Phase IIa Trial for the Treatment of EndometriosisJan Hilpert, Esther Groettrup-Wolfers, Hristiyan Kosturski, et al.
Drugs in R&D|January 9, 2003
Six-month toxicity study of oral administration of D-003 in Sprague Dawley ratsRafael Gámez, Rosa Más, Miriam Noa, et al.
Drugs in R&D|November 29, 2002
Assessment of the effects of D-003, a new antiplatelet and lipid-lowering compound, in healthy volunteers. A phase I clinical studyGladys Castaño, Rosa Más, Lilia Fernández, et al.
Pageof 90